Volume 10, Number 9—September 2004
CTX-M β-Lactamase-producing Escherichia coli in Long-term Care Facilities, France
Highlight and copy the desired format.
|EID||Kassis-Chikhani N, Vimont S, Asselat K, Trivalle C, Minassian B, Sengelin C, et al. CTX-M β-Lactamase-producing Escherichia coli in Long-term Care Facilities, France. Emerg Infect Dis. 2004;10(9):1697-1698. https://dx.doi.org/10.3201/eid1009.030969|
|AMA||Kassis-Chikhani N, Vimont S, Asselat K, et al. CTX-M β-Lactamase-producing Escherichia coli in Long-term Care Facilities, France. Emerging Infectious Diseases. 2004;10(9):1697-1698. doi:10.3201/eid1009.030969.|
|APA||Kassis-Chikhani, N., Vimont, S., Asselat, K., Trivalle, C., Minassian, B., Sengelin, C....Arlet, G. (2004). CTX-M β-Lactamase-producing Escherichia coli in Long-term Care Facilities, France. Emerging Infectious Diseases, 10(9), 1697-1698. https://dx.doi.org/10.3201/eid1009.030969.|
To the Editor: In long-term care facilities, most endemic infections affect respiratory and urinary tracts, as well as skin and soft tissues (1–3). Infection and colonization by antimicrobial-resistant organisms, in particular those producing plasmid-mediated extended-spectrum β-lactamases (ESBL), are common in long-term care facilities (4). Since 1984, ESBL-producing Enterobacteriaceae have spread among French hospitals; within Parisian public hospitals (Assistance Publique, Hôpitaux de Paris), ESBL-producing Escherichia coli is the most frequent species found, representing 49.5% of 220 Enterobacteriaceae isolated in 2002, mostly in urinary tract infections (5). Among ESBL-producing Enterobacteriaceae, CTX-M–type β-lactamases confer a higher level of resistance to cefotaxime and ceftriaxone than to ceftazidime. CTX-M–producing strains are endemic in Latin America, Japan, and certain parts of Eastern Europe; in contrast, these strains are emerging in France, Western Europe, and the United States (6). We report the first documented outbreak of CTX-M–producing E. coli infection in a long-term care facility in France. Our hospital is an 800-bed institution with 300 beds for long-term patients distributed among three units located in two buildings. The outbreak occurred in a 35-bed unit and involved 26 of 47 hospitalized patients from October 2001 to March 2003. This facility hosts patients for extended periods of time or permanently. The index case was identified in October 2001; the patient had a urinary tract infection attributable to an ESBL-producing E. coli, which showed resistance patterns not previously found in our hospital. Three new cases were detected within the following 2 months, and all patients had urinary tract infection with the same pattern of resistance. In January 2002, patients were screened for ESBL-producing strains by rectal swabbing and urine culture. The results showed E. coli with a high level of resistance to amoxicillin and ticarcillin MIC > 128 μg/mL, partial restoration of susceptibility to these agents by addition of clavulanic acid MIC = 16–32 μg/mL), and higher resistance to cefotaxime MIC > 128 μg/mL) than to ceftazidime MIC = 32–64 μg/mL.) A cephalosporin/co-amoxiclav synergy test was positive, which suggests a CTX-M ESBL. Strains were also resistant to ciprofloxacin MIC 64 μg/mL and gentamicin MIC > 64 μg/mL) but remained susceptible to trimethoprim-sulfamethoxazole.
Attempts to transfer resistance to β-lactams by conjugation to E. coli J53-2 with the 26 strains tested were unsuccessful. In contrast, transformants were obtained with plasmid DNA of the 19 strains tested by electroporation. The transformants’ susceptibility pattern was similar to that of the donor strains, except for ciprofloxacin resistance. Analytical isoelectric focusing showed that all clinical strains and transformants had bands of β-lactamase activity with an alkaline pI of 7.6 and 5.4. Polymerase chain reaction (PCR) amplification of the 26 clinical isolates was positive for blaCTX-M and blaTEM (7). The 26 strains of E. coli had the same profile by repetitive-element PCR and pulsed-field gel electrophoresis, while unrelated control strains had very different profiles. Sequencing in strains isolated from four of the patients identified a CTX-M-15 β-lactamase and a TEM-1 β-lactamase. The four strains were related to the phylogenetic group B2 and produced the iutA (ferric aerobactin receptor), YuA (Yersinia siderophore receptor), and fimH (type I fimbriae) virulence factors (8). Incidence of colonization or infection by the culprit strain was 34.3% (12 of 35 patients) within the initial 4-month period and 55.3% (26 of 47 patients) over a 1-year period.
Intensified hygienic procedures implemented in January 2002 contributed to a decrease in the number of cases in February only; since then, a regular increase of new cases extended the outbreak and caused problems with controlling it. All urinary tract infections were successfully treated with a 15-day course of trimethoprim-sulfamethoxazole; however, reinfection occurred in some. Neither incontinence (p = 0.35), dementia (p = 0.22), nor previous antibiotic treatment (amoxicillin, amoxicillin-clavulanic acid, extended-spectrum cephalosporins, and fluoroquinolones [p = 1.00, 0.30, 0.12, 0.52, respectively]) appeared to be risk factors for infection or colonization in our study, but the number of patients is too small to reach a conclusion. However, patients that were infected or colonized had greater functional impairment, especially incontinence and dementia. Nonambulatory status, decubitus ulcers, and feeding tubes were not risk factors for acquiring ESBL-producing E. coli in our study.
The outbreak has not been controlled: 13 patients have persistent digestive-tract colonization. Difficulties encountered in controlling such outbreaks may be explained by several factors. Patients cannot be easily isolated in long-term care facilities. Strict isolation and limitation of activity and mobility cannot always be applied because of their impact on social activities.
We thank Abel Naas for helping to collect the clinical information and Claudia Ferreira for helping to write this letter.
- Nicolle LE, Garibaldi R, Strausbaugh LJ. Infections and antibiotic resistance in nursing homes. Clin Microbiol Rev. 1996;9:1–17.
- Nicolle LE. Infection control in long-term care facilities. Clin Infect Dis. 2000;31:752–6.
- Muder RR. Pneumonia in residents of long-term care facilities: epidemiology, etiology, management, and prevention. Am J Med. 1998;105:319–30.
- Wiener J, Quinn JP, Bradford PA, Goering RV, Nathan C, Bush K, Multiple antibiotic resistant Klebsiella and Escherichia coli in nursing homes. JAMA. 1999;281:563–4.
- Gutmann L, Jarlier V, Nicolas-Chanoine MH, Soussy CJ. Staphylocoques dorés et klebsielles à l’AP-HP. Résultats de l’enquête 2002. Department of Microbiology, Assistance Publique, Hôpitaux de Paris; 2003.
- Bonnet R. Growing group of extended spectrum beta-lactamases: CTX-M enzymes. Antimicrob Agents Chemother. 2004;48:1–14.
- Eckert C, Gautier V, Saladin-Allard M, Hidri N, Verdet C, Ould-Hocine Z, Dissemination of CTX-M-Type beta-lactamases among clinical isolates of Enterobacteriaceae in Paris, France. Antimicrob Agents Chemother. 2004;48:1249–55.
- Johnson JR, Russo TA. Extraintestinal pathogenic Escherichia coli: “the other bad E. coli. J Lab Clin Med. 2002;139:155–62.
Please use the form below to submit correspondence to the authors or contact them at the following address:
Najiby Kassis-Chikhani, Hôpital Paul Brousse, Service de Microbiologie, 12 Ave P.V. Couturier 94804, Villejuif Cédex, France; fax: 33-1-45-59-37-24
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: March 25, 2011
- Page last updated: March 25, 2011
- Page last reviewed: March 25, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)